Combination Antiangiogenic and Immunotherapy for Advanced Hepatocellular Carcinoma: Evidence to Date

For over a decade, sorafenib remained the only systemic agent with proven clinical efficacy for patients with advanced hepatocellular carcinoma (HCC). Recent years have seen a proliferation of agents. In the first line, lenvatinib was found to be non-inferior to sorafenib in terms of overall surviva...

Descripción completa

Detalles Bibliográficos
Autores principales: Raybould, Alison L, Sanoff, Hanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7501959/
https://www.ncbi.nlm.nih.gov/pubmed/32984090
http://dx.doi.org/10.2147/JHC.S224938

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7501959/
https://www.ncbi.nlm.nih.gov/pubmed/32984090
http://dx.doi.org/10.2147/JHC.S224938

Ejemplares similares